[Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].
OBJECTIVE
To compare the efficacy and safety of domestic piperacillin/tazobactam with those of Timentin in treatment of acute bacterial infections.


METHODS
A randomized controlled multicentre trial and an opening clinical trial were conducted in 4 hospitals in Beijing.


RESULTS
The cure and efficacy rates in the test group were 73.0% (46/63) and 96.8% (61/63), respectively and the bacterial clearance rate was 91.7% (55/60). The cure and efficacy rates in the control group were 58.7% (37/63) and 97.7% (43/44) respectively, and the bacterial clearance rate was 87.9% (51/58). The difference between the two groups was not statistically significant. The cure rate, efficacy rate and bacterial clearance rate in the opening group were 72.7% (32/44), 97.7% (43/44) and 88.4% (38/43) respectively. No serious adverse drug reaction was found during the treatment with piperacillin/tazobactam.


CONCLUSIONS
Domestic piperacillin/tazobactam is effective and safe for the treatment of acute bacterial infections.
Liu
Y
Y
Department of Respiratory Diseases, Chinese PLA General Hospital, Beijing 100853, China.
Wang
R
R
Yu
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010878:Piperacillin / Q000009:adverse effects / Q000627:therapeutic use*; D012871:Skin Diseases / Q000139:chemically induced; D000078142:Tazobactam; D016896:Treatment Outcome
D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin